Designing primate models to assess the prodromal phase of Huntington's disease

Revue Neurologique

Volumn 168, Issue 11, 2012, Pages 802-805

  Aron Badin, R ^a   Hantraye, P ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Huntington's disease; Neuronal dysfunction; Neuroprotection; Presymptomatic phase; Primate models

Indexed keywords

ARTICLE; CAUDATE NUCLEUS; COGNITIVE DEFECT; DISEASE COURSE; EXPERIMENTAL MODEL; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PRIMATE; VALIDATION STUDY;

EID: 84869081302     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2012.07.002     Document Type: Review

References (25)

1. M.F. Beal, N.W. Kowall, D.W. Ellison, M.F. Mazurek, K.J. Swartz, and J.B. Martin Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid Nature 321 1986 168 171
2. E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroy-Willig, and N.W. Kowall Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates Proc Natl Acad Sci USA 92 1995 7105 7109
3. L.H. Burns, P. Pakzaban, T.W. Deacon, A.L. Brownell, S.B. Tatter, and B.G. Jenkins Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease Neuroscience 64 1995 1007 1017
4. A.W. Chan, K.Y. Chong, C. Martinovich, C. Simerly, and G. Schatten Transgenic monkeys produced by retroviral gene transfer into mature oocytes Science 291 2001 309 312
5. C. Dautry, F. Condé, E. Brouillet, V. Mittoux, M.F. Beal, and G. Bloch Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid Neurobiol Dis 6 1999 259 268
6. C. Dautry, F. Vaufrey, E. Brouillet, N. Bizat, P.G. Henry, and F. Condé Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid J Cereb Blood Flow Metab 20 2000 789 799
7. L.P. De Almeida, C.A. Ross, D. Zala, P. Aebischer, and N. Déglon Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length J Neurosci 22 2002 3473 3483
8. M. DiFiglia Excitotoxic injury of the neostriatum: a model for Huntington's disease Trends Neurosci 13 1990 286 289
9. S.B. Dunnett, and S.D. Iversen Learning impairments following selective kainic acid-induced lesions within the neostriatum of rats Behav Brain Res 2 1981 189 209
10. R.J. Ferrante, N.W. Kowall, P.B. Cipolloni, E. Storey, and M.F. Beal Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization Exp Neurol 119 1993 46 71
11. P. Hantraye, D. Riche, M. Maziere, and O. Isacson A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon Exp Neurol 108 1990 91 104
12. M.P. Heyes, K.J. Swartz, S.P. Markey, and M.F. Beal Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease Neurosci Lett 122 1991 265 269
13. I. Kanazawa, Y. Tanaka, and F. Cho Choreic" movement induced by unilateral kainate lesion of the striatum and L-DOPA administration in monkey Neurosci Lett 71 1986 241 246
14. A.L. Kendall, F.D. Rayment, E.M. Torres, H.F. Baker, R.M. Ridley, and S.B. Dunnett Functional integration of striatal allografts in a primate model of Huntington's disease Nat Med 4 1998 727 729
15. J.B. Martin Huntington's disease: new approaches to an old problem. The Robert Wartenberg lecture Neurology 34 1984 1059 1072
16. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, and C. Hetherington Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506
17. L.B. Menalled, and M.F. Chesselet Mouse models of Huntington's disease Trends Pharmacol Sci 23 2002 32 39
18. V. Mittoux, J.M. Joseph, F. Conde, S. Palfi, C. Dautry, and T. Poyot Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease Hum Gene Ther 11 2000 1177 1187
19. S. Palfi, R.J. Ferrante, E. Brouillet, M.F. Beal, R. Dolan, and M.C. Guyot Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease J Neurosci 16 1996 3019 3025
20. S. Palfi, F. Conde, D. Riche, E. Brouillet, C. Dautry, and V. Mittoux Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease Nat Med 4 1998 963 966
21. S. Palfi, L. Leventhal, C.G. Goetz, T. Hantraye, B.Z. Roitberg, and J. Sramek Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys Mov Disord 15 2000 524 530
22. S. Palfi, E. Brouillet, B. Jarraya, J. Bloch, C. Jan, and M. Shin Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates Mol Ther 15 2007 1444 1451
23. E. Régulier, Y. Trottier, V. Perrin, P. Aebischer, and N. Déglon Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum Hum Mol Genet 12 2003 2827 2836
24. E. Sasaki, H. Suemizu, A. Shimada, K. Hanazawa, R. Oiwa, and M. Kamioka Generation of transgenic non-human primates with germline transmission Nature 459 2009 523 528
25. J.M. Schumacher, P. Hantraye, A.L. Brownell, D. Riche, B.K. Madras, and P.D. Davenport A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures Cell Transplant 1 1992 313 322